Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

The main purpose of this study is : To establish which number of doses of gemtuzumab ozogamicin (up to a maximum of 3 doses) is tolerated and can be safety delivered in combination

mitoxantrone
gemtuzumab
minimal residual disease
ara-c
neoadjuvant therapy
  • 0 views
  • 26 Jan, 2022
  • 69 locations
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by

methotrexate
mitoxantrone
adult acute myelogenous leukemia
gemtuzumab
cell transplantation
  • 141 views
  • 10 May, 2022
  • 98 locations
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RAR transcript and less than 18 years of age.

  • 0 views
  • 21 Mar, 2021
  • 29 locations
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

This phase Ib trial studies the best dose of gemtuzumab ozogamicin when given together with CPX-351 in treating patients with acute myeloid leukemia that has come back after it was previously in

blast cells
cancer
remission
daunorubicin
gemtuzumab
  • 1 views
  • 27 May, 2022
  • 1 location
Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

MRD driven study. Addition of gemtuzumab to conventional chemotherapy to reduce MRD of patients with favorable/intermediate-risk AML. Post-consolidation assessment of MRD. Role of a post-SCT

gemtuzumab
myelodysplastic syndromes
acute promyelocytic leukemia
serum bilirubin level
blast cells
  • 0 views
  • 21 Jul, 2022
  • 18 locations
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

This phase I/Ib trial studies the side effects and best dose of talazoparib given together with gemtuzumab ozogamicin and to see how well they work in treating patients with CD33 positive acute

  • 0 views
  • 11 Jul, 2022
  • 2 locations
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

. Researchers are studying whether the drug Gemtuzumab Ozogamicin, followed by an infusion of blood cells called leukocytes from a donor, can stimulate the immune system to potentially fight the leukemia

gemtuzumab
acute leukemia
hla-a
cancer
fludarabine
  • 3 views
  • 15 May, 2022
  • 1 location
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia. Drugs

gemtuzumab ozogamicin
tretinoin
cancer
idarubicin
serum pregnancy test
  • 26 views
  • 30 May, 2022
  • 5 locations
A Phase 2 Trial of Fractionated Gemtuzumab Ozogamicin to Eradicate Measurable Residual Disease in Acute Myeloid Leukemia Patients (GO for MRD)

This phase II trial studies the how well fractionated gemtuzumab ozogamicin works in treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a

gemtuzumab ozogamicin
gemtuzumab
myeloid leukemia
acute promyelocytic leukemia
cancer
  • 5 views
  • 15 Sep, 2022
  • 1 location
A Phase I Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (AML)

This phase I trial studies the best dose and side effects of liposomal cytarabine, daunorubicin, and gemtuzumab ozogamicin in treating pediatric patients with acute myeloid leukemia that has

  • 0 views
  • 20 Sep, 2022
  • 1 location